ABCA3-related interstitial lung disease beyond infancy


ABSTRACT

Background The majority of patients with childhood interstitial lung disease (chILD) caused by pathogenic variants in ATP binding cassette subfamily A member 3 (ABCA3) develop severe respiratory insufficiency within their first year of life and succumb to disease if not lung transplanted. This register-based cohort study reviews patients with ABCA3 lung disease who survived beyond the age of 1 year.

Method Over a 21-year period, patients diagnosed as chILD due to ABCA3 deficiency were identified from the Kids Lung Register database. 44 patients survived beyond the first year of life and their long-term clinical course, oxygen supplementation and pulmonary function were reviewed. Chest CT and histopathology were scored blindly.

Results At the end of the observation period, median age was 6.3 years (IQR: 2.8–11.7) and 36/44 (82%) were still alive without lung transplantation, and disease course appeared dependent on the specific ABCA3 sequence variation.

Conclusion The natural history of ABCA3-related interstitial lung disease progresses during childhood and adolescence. Disease-modifying treatments are desirable to delay such disease course.

INTRODUCTION

ABCA3 (ATP binding cassette subfamily A member 3) is a lipid transport protein anchored to the outer membrane of lamellar bodies (LBs) in alveolar type 2 lung cells. By transporting phosphatidylcholine and other lipids from the cytoplasm into LBs to assemble pulmonary surfactant, ABCA3 plays a critical part in normal surfactant metabolism. Mutated ABCA3 is a prominent genetic cause for diffuse interstitial or parenchymal lung disease in childhood (chILD).1,2

There is a strong genotype-phenotype correlation in chILD caused by ABCA3 sequence variants. Variants can be grouped according to their effect on ABCA3 function into ‘null’ and ‘homo- morphic’ variants. ‘Null’ variants do not produce functional protein due to frameshift variants or nonsense variants, or the deletion of an entire exon.
‘Hypomorphic’ mutations often result from missense variants, in-frame insertions or deletions and are predicted to result in an ABCA3 transporter protein with some residual functions.5

Reviewing the published literature, about two-thirds of the patients reported to date presented during the neonatal period, had a severe clinical course with global respiratory insufficiency and died in the first year of life.6,7 The literature search for children surviving beyond their first birthday retrieved very limited data from a total of 43 subjects from various case reports or mini-series.5-29 Patients surviving longer often carried a compound heterozygous genotype and had less oxygen supplementation during the neonatal period. Clinical characteristics of patients who survived longer have not been systematically reported yet.

Here, we detail the history, clinical phenotype, imaging and their relation to disease causing mutations of a cohort of 44 patients with ABCA3-related interstitial lung disease (ILD) who survived beyond infancy.

METHODS

Patients

This cohort study investigates a group of patients with lung disease caused by ABCA3 variants. The patients were collected in the Kids Lung Register (KLR) database between January 2001 (establishment of KLR) and April 2021. We screened all patients with an ILD defined by the presence of tachydyspnnea, hypoxaemia and diffuse abnormalities on imaging2,30 and who were tested for ABCA3 variants. Included in this analysis were patients carrying homozygous or compound heterozygous ABCA3 variants. We focused on children who had survived without lung transplantation beyond the first year of life (online supplemental table S1). Patients who had died before the age of 1 year are listed in online supplemental table S2.

GENETIC ANALYSIS

For genetic analyses, genomic DNA was isolated from whole blood (QIAmp DNA Mini Kit, Qiagen), and ABCA3 was analysed using Sanger sequencing.31 In some cases, ABCA3 variants were detected by whole exome analysis.32 Prediction of the pathogenicity of the variants was conducted with PROVEAN V1.1.3,33 PolyPhen-234 and ClinVar.35 Since functional studies quantifying potential residual ABCA3 function in the previously unreported variants are not part of this work, their assignment as ‘hypomorphic’ variants is based on the in silico prediction tools stated above and might not reflect true biological function.

CLINICAL DATA

Data on the clinical course and oxygen supplementation of the patients were retrieved from the register. Age at onset of chILD was defined as the time of first observed respiratory abnormalities or failure to thrive. Baseline referred to the relative clinical manifestation of the patients at their inclusion. The history and current oxygen supplementation were recorded at each clinic visit. Methods of oxygen supplementation included nasal cannula, face mask or various modes of ventilation support. Overall, we characterised four patterns of oxygen supplementation: (A) oxygen never required since onset of disease; (B) persistent oxygen required since onset of disease; (C) need for oxygen one or multiple times after disease onset, but not at the last visit and (D) need for oxygen one or multiple times including at the last visit.

Pulmonary function test information of patients in the register was collected from about age 4 years, onward at least baseline, 12 months and then annual data. Forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) were expressed as percent predicted using GLI-2012 reference values.10

High-resolution CT analysis

High-resolution CT (HR-CT) was centrally peer reviewed by agreement of three paediatric radiologists paediatric radiologists (JL-Z, BK and IK) and scored according to the criteria of Fleischner Society.36 The presence or absence of ground glass opacities (GGOs), diffuse or patchy, nodules or nodular opacities, focal consolidations (excluding dependent atelectasis), cystic parenchymal lesions, emphysema, bronchial wall thickening, (traction)-bronchiectasis, mosaic perfusion and mosaic attenuation, air trapping during expiration and fibrotic signs including linear or reticular opacities, honeycombing and architectural distortion, were differentiated.

Figure 1 Flow chart of patient inclusion and survival analysis of patients with two ABCA3 variants in KLR. (A) All patients were enrolled from Kids Lung Register. Numbers in dashed frame: excluded patients. Numbers in solid line frame: included patients. LTX: lung transplantation. (B) For patients who went through genetic tests and diagnosed with biallelic ABCA3 variants, their survival rate was analysed according to different genotypes: hypo/hypo, hypo/null and null/null. chILD, childhood interstitial lung disease; ILD, interstitial lung disease.
Lung biopsy histology
All lung biopsies initially analysed by a local pathologist were centrally re-evaluated according to a standardised protocol by a pathologist trained and specialised in paediatric ILDs. Extent of histological changes was scored by severity (0=none, 1=discrete, 2=moderate and 3=strong) with respect to the localisation of the changes (see figure 5A) and the expression of individual histopathological features (see figure 5B).37

Statistics
Data sets retrieved from the data base were checked for missing or implausible values. All contributing investigators were asked to complete the data as much as possible from local patient records. Statistical analysis was done with GraphPad Prism V8. Grouped data were compared by unpaired t-tests, and Kaplan-Meier survival curves were assessed by log-rank tests. Imaging or histological data are available on request.

RESULTS
Patient cohort
Between January 2001 and April 2021, 398 of 1707 patients with chILD included in the KLR database were tested for ABCA3 sequence variations; the disease categories of those who were not tested are listed in online supplemental table S3. Genetic testing was discussed for all subjects and selection was advised by the chILD experts of the register, but the submitting physician made the final decision. Among these individuals 142 carried at least one ABCA3 variant and 79 carried 2 variants. Patients who received lung transplantation, died or were lost to follow-up in the first year of life were excluded (35/79), leaving 44/79 patients with biallelic variants included in the final cohort (figure 1A). 67.6% and 62.5% patients with biallelic variants classified as hypo/hypo or hypo/null genotype survived beyond 1 year, respectively, while only 15.4% null/null patients survived 1 year (figure 1B). In about half of the patients (n=21) lung disease started in the neonatal period (figure 2A). Fourteen patients carried homozygous ABCA3 variants, while 30 carried
compound heterozygous variants. Grouping these patients according to the predicted functional consequences of the variants gave 37 patients carrying ‘hypo/hypo’, 5 ‘hypo/null’ and 2 ‘null/null’ variants (online supplemental table S1 and S4). The most common variant identified in our patients was p.E292V (allele frequency: 13/88), followed by p.R43H, p.R208W and p.G964D (allele frequency: 4/88). The frequency of the other variants was either 2/88 or 1/88 (online supplemental table S1). During the observation period, 8 of the 44 patients died or received lung transplantation (online supplemental table S1, figure 1B). Twenty-seven per cent (10/37) patients with ‘hypo/hypo’ genotype survived beyond 12 years of age.

Oxygen supplementation of patients at the last follow-up visit

We used patients’ oxygen requirement as a proxy for chronic respiratory insufficiency during survival. More than 50% of the patients needed additional oxygen in the first 6 months after baseline, while thereafter the frequency varied between 20% and 50% and dropped to about 10% in patients older than 16 years (figure 2B). At their last clinical evaluation, 9 patients were 1–3 years old, 10 were 3–6 years old, 7 were between 9 and 12 years, 4 were between 12 and 15 years, and 9 were older than 15 years (figure 2C). Overall, 15 of the 44 patients (34%) never required oxygen after disease onset and 10 patients (22.7%) were completely dependent on supplemental oxygen. Nineteen patients (43.2%) needed oxygen once or multiple times after disease onset, of these 11 did not use supplemental oxygen at their last clinical visit (figure 2D). Median survival for patients never requiring oxygen (9.7 years (95% CI 6.7 to 27.7)) was longer compared with those dependent on oxygen (3.0 years (95% CI 1.5 to 5.0)) (p=0.0126, figure 2D).

Pulmonary function test results reveal lung function decline over time

Serial PFT results were available in 17 of 26 patients able to perform lung function tests (figure 3). The individual level of lung function varied widely between patients and were larger than the intranidividual changes over time. Despite rising and falling levels at different tests, lung function in the majority of subjects (12/17) deteriorated, when comparing the first and last tests. In patient P1, expiration time was too short to obtain FEV1 values. This subject was omitted from regression analysis. MMRMs regression demonstrated an impact of age on FEV1 % predicted (p=0.0002) and on FVC % predicted (p=0.0171). Average loss for FVC % predicted was about 1.1% predicted per year and for FEV1 % predicted was about 1.7% predicted per year. Of interest was the observation that in addition to restrictive pattern of lung function impairment, we also noted obstructive pattern in several subjects (figure 3A, B).

Chest HR-CT indicated GGO was a common and sustained pattern in all patients

Chest CTs were available in 23 patients. To analyse whether the CT patterns changed with age, CT scans were divided into those performed at less than 2 years of age and greater than 2 years. The three most common CT patterns in the younger group were GGOs, linear or reticular opacities and focal consolidations. In the older patients, the three most common CT patterns were GGO, linear or reticular opacities and cystic parenchymal lesions. The frequency of cystic parenchymal lesions in patients older than 2 years of age was higher compared with the younger group (p=0.0306), suggesting that the presence of cystic parenchymal lesions might serve as a potential progression marker of ABCA3 lung disease (figure 4A). Seven patients had repetitive CT scans, demonstrating the interindividual heterogeneity of findings and progression with time (figure 4B).

Various histology patterns in lung biopsies at the time of diagnosis

Due to advances in rapid genetic diagnosis of surfactant dysfunction disorders, nowadays lung biopsies are done very infrequently. Therefore, we included this treasure of data on histological analysis. Only seven patients had lung tissue obtained at initial diagnosis of chILD. Four patients had chronic pneumonitis of infancy (CPI, P1, P12, P17 and P43), one had chronic bronchiolitis (P29), one mixed non-specific interstitial pneumonia (mNSIP, P23) and one had desquamative interstitial pneumonia (DIP, P33). One patient had combined CPI and DIP (P1). Semiquantitative rating of the histopathological features showed a predominantly diffuse and heterogeneous distribution of the features, affecting mainly the alveoli (figure 5A). Four patients were observed to display airway abnormalities, including chronic lymphocytic inflammation, acute neutrophilic inflammation and follicular hyperplasia (figure 5B). The major histopathological deviations involved the alveolar/interstitial region. The most common and severe histological abnormalities
were type II pneumocyte hyperplasia, alveolar enlargement and alveolar septal thickening (figure 5C).

**Correlating survival and location of type of genetic variation in ABCA3**

The variants identified scattered over the entire ABCA3 gene, among them was the known hotspot E292V (figure 6A). In the 44 patients described above who survived their first year of life, survival was independent of the domain location of their variants. To assess the relationship between domain location of variants and survival further, we included the 33 patients who died or received lung transplantation before the age of 1 year (figure 6A,B). We compared the locations of the allele frequencies between these two survival groups. Patients with variants located in the intracellular helix 2 (IH2, p=0.012) and TMD2_P1 (p=0.016) had a longer survival, whereas patients with variants in helix 2 (p=0.0001) were more likely to die before the age of 1 year (figure 6C).

Generally, patients with homozygous mutation died earlier; an exception were patients P34 and P36 who carried homozygous p.G964D variants and survived into adulthood. For some variants the evidence of pathogenicity was weaker than for others; for these all supportive data from lung pathology, lavage measurements or in vitro data were detailed (online supplemental table S5).

**Medication during the course**

Medication information was available in 39 patients. Systemic glucocorticosteroids, hydroxychloroquine (HCQ) and macrolides were the major drugs used (online supplemental figure S1A). Steroids were often combined with HCQ and macrolides (online supplemental figure S1B). Due to lack of reliable time dependent data on treatment, no calculations on the impact of these treatments could be made.

**DISCUSSION**

In this study, we present comprehensive clinical characteristics on 44 patients carrying biallelic ABCA3 variants and surviving beyond infancy. Repeated clinical observations of oxygen supplementation, lung function and clinically indicated chest HR-CTs were suitable outcome parameters describing the long-term course of molecularly defined ABCA3 lung disease during childhood and adolescence. Genotype was a prognostic indicator for the patients in our cohort. ‘Hypo/hypo’ variants were present in 37 patients and 5 patients carried ‘hypo/null’ variations. It must be noted that due to lack of comprehensive in vitro data the degree of residual function in variants characterised as ‘hypo’ likely varies and may possibly include functional ‘null’ variants. One ‘null/null’ patient with homozygous truncation variants died at age 1 year and 5 weeks, and another ‘null/null’ patient received lung transplantation at the age of 1.5 years. These findings were in accordance with published data.3 We attempted to link the position of the patients’ variants on ABCA3 protein domains to the maximal age of their carrier. Although variants located in helix2 and NBD2 were associated with shorter survival, domain distribution of the variants did not strongly indicate the prognosis of the patients.

ABCA3 deficiency is a severe condition even in survivors beyond the first year of life—4/44 of the patients in this cohort died before 5 years of age. We noticed later disease onset being
Associated with improved survival and less or even no need for oxygen supplementation. This observation is in agreement with recently published data on three cases of ABCA3 deficiency presenting in adulthood. Repeated lung function measurements were available in fourteen children beyond the age of 4 years. Overall, lung function impairment was restrictive or mixed obstructive/restrictive. Of interest, the level of FVC varied widely between different patients already at the start of measurement at age of 4–6 years. This very likely reflected the severity or extent of lung disease, which had developed during infancy and early childhood. We trusted and presented all clinically obtained measurements even at low age, as subjects were trained and values could be reproduced well. Over time and for the whole group of patients, the trajectories of lung function decreased from about 74.7% to 47.6% for FVC % predicted and to 34.3% for FEV1 % predicted during a 24-year period (from 4 to 28 years old), that is, yielding an average loss of FVC % predicted of 1.1% per year. These predictions are in accordance with the low level of lung function values reported for two other patients in the literature, a 41-year-old with a FEV1 % predicted of 49%, and a 61-year-old with a FVC % predicted of 49%.

Up to date, there is very little data on CT pattern of patients with ABCA3 deficiency and its evolution beyond the first year of life. In children younger than 2 years typical features of fibrosis (honeycombing, architectural distortion, (traction)-bronchiectasis) were observed infrequently. All these features appeared to increase with age. In particular, the presence of cystic parenchymal lesions increased from approximately 10% to a prevalence of 60% in older patients. Previously, GGOs were reported to be the most common CT pattern, which matches with our data; we further observed a shift in the distribution of the GGOs from a diffuse in the younger patients (<1-year-old) to a patchy in older patients (>5-year-old). Taken together, CT imaging demonstrated a progression of the ILD over time.

Currently, there are no biomarkers for disease progression in ABCA3 deficiency. To aid clinical management of patients, we provide longitudinal data on lung function and chest HR-CT scans in a suitable number of patients. Our data suggest that pathogenic variants in some domains of ABCA3 like IH2, TMD1 and TMD2 may be linked to longer survival. Further data are necessary to confirm this. Genetic analysis of a blood sample allows little invasive molecular diagnosis of ABCA3 deficiency. Thus, today lung biopsies are rarely performed, therefore the biopsies were mainly done during the first decade of our observation period and were now reread in a standardise manner by a single specialized pathologist. Except for a patient with some evidence for fibrosis due to the pattern of mNSIP, none of the subjects had fibrosing lung disease on histology. The major hallmark was the predominant involvement of the alveolar and interstitial region, with a type II pneumocyte hyperplasia, alveolar septal thickening, macrophage accumulation, often minor alveolar proteinosis or lipid pneumonia pattern. Immune cell infiltration was mainly lymphocytic, which might give a clue for anti-inflammatory treatment. Of importance, alveolar simplification was mainly lymphocytic, which might give a clue for anti-inflammatory treatment. Of importance, alveolar simplification was mainly lymphocytic, which might give a clue for anti-inflammatory treatment. Of importance, alveolar simplification was mainly lymphocytic, which might give a clue for anti-inflammatory treatment. Of importance, alveolar simplification was mainly lymphocytic, which might give a clue for anti-inflammatory treatment. Of importance, alveolar simplification was mainly lymphocytic, which might give a clue for anti-inflammatory treatment. Of importance, alveolar simplification was mainly lymphocytic, which might give a clue for anti-inflammatory treatment.

This study has some limitations. First, the composition of the study cohort was dependent on the nature of patients submitted to the register. Subjects with a different or very mild phenotype might not have been tested for ABCA3 deficiency and thus not included into the study; this concerns in addition some of those patients who could not assess due to lack of data, genetic material or consent (online supplemental table S3). On the other hand, we may have included patients with a fitting clinical or pathological phenotype, however, with weak or lacking data on variant pathogenicity for ABCA3 deficiency (online supplemental table S5). An unbiased population-based approach would be necessary to solve these issues. However, this may be costly and has other, in particular ethical problems due to the detection of asymptomatic carriers or variants of unknown significance. Second, age and follow-up time were broadly variable between subjects, yielding incomplete longitudinal data and asymptomatic children might no longer be seen at clinical visits. Third, caution is necessary when correlating genotype and associated outcome. In patients carrying compound heterozygous pathogenic variants the effect of the two mutations may be asymmetrical or additional yet unknown interactions may play a role. Due to the limited observation times for some variants and the absence of detailed treatment recordings, associated prognosis can be erroneous. The strength of this investigation includes the generation of a good size cohort of subjects over a period of 20 years with standardised assessment of HR-CT imaging and histopathology by experts specialised in paediatric radiology and pathology and blinded to the molecular diagnosis.
Figure 6  Domain organisation of ABCA3 sequence variations observed in the cohort collected by the Kids Lung Register. (A) Frameshift, nonsense, missense, splice site, in-frame insertion/deletion variants were plotted according to the amino acid site, intronic variants not indicated. Variants plotted in blue: carrier survived beyond 1 year; plotted in orange: patients’ death before 1 year; edged yellow or blue dots: homozygous variants; dots with asterisk: compound heterozygous mutations. The position of TMDs and NBDs of ABCA3 were referred to the prediction algorithms of Onnée et al.\textsuperscript{40} (B). Age of survival of the mutations’ carrier (y-axis) in dependency of amino acid position (x-axis). For variants occurring in multiple patients, median survival age of carriers was indicated. Blue dots with yellow edge: homozygous variants; flat dots without edge: compound heterozygous variants. Number(s) inside dots: No of patients as listed in online supplemental table S1. Asterisk inside p.E292V dot indicated this variant was carried by multiple patients. (C) Allele frequency of variants for patients surviving >1 year or <1 year was counted in each domain and compared by Fisher’s exact test (*p<0.05, ***p<0.001). IHS, intracellular helices. TMD1\textsubscript{P1}: part 1 of transmembrane domain 1, from p.K21 to p.R289. TMD1\textsubscript{P2}: part 2 of transmembrane domain 1, from p.S301 to p.G450. TMD2\textsubscript{P1}: part 1 of transmembrane domain 2, from p.M925 to p.Q1126. TMD2\textsubscript{P2}: part 2 of transmembrane domain 2, from p.S1134 to p.E1325 (NP_001080.2). EHs, exocytoplasmic helices; IHs, intracellular helices; PHs, pinning helix; RDs, regulatory domains.

This study provides details on the longitudinal history of ABCA3-related ILD of patients surviving beyond infancy into early adulthood. We provide evidence for progressive fibrosing lung disease based on lung function course and HR-CT changes. Such knowledge in rare and molecularly defined entities is very important to define the characteristics of cohorts for interventional trials of novel treatment approaches.39

Author affiliations
1Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-University, Munich, Germany
2German Center for Lung Research (DZL), Munich, Germany
3Medical college, Chongqing University, Chongqing, China
4Department of Pathology, Würzburg University, Würzburg, Germany
5Department of Radiology, Pediatric Radiology, University Hospital, Ludwig-Maximilians-Universität Munich, Munich, Germany
6Department of Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hanover, Germany
7German Center for Lung Research (DZL), BREATHE Hanover, Hanover, Germany
8Department of Pediatric Pulmonology, Allergology and Neonatology, Hannover Medical School, Hanover, Germany
9Department of Pediatrics, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, Barcelona, Spain and CIBER of Rare Diseases (CIBERER), Instituto de Salud Carlos III (ISCIII), Madrid, Spain
10Department of Pediatric Pneumology and Allergy, Medical University of Warsaw, Warsaw, Poland
11Department of Pediatrics, Makassed Charitable Society Hospital, East Jerusalem, Palestine
12Regional Paediatric CF Centre, Alder Hey Children’s Hospital, Liverpool, UK
13Department of Pediatric Pulmonology, Gazi University Faculty of Medicine, Ankara, Turkey
14Pediatric Respiratory Medicine, Children’s Hospital, Luzern, Switzerland
15Department of Pediatrics, University Hospitals Leuven, Leuven, Belgium
16Children’s Hospital, Department of Pneumology, University Hospital Essen, Essen, Germany
17Department of Pediatrics, Justus-Liebig-University Giessen, German Center for Lung Research, Justus-Liebig-University Giessen, Giessen, Germany
18Cerrahpaşa University, Istanbul, Turkey
19Darmstädter Kinderkliniken Prinzessin Margaretha, Darmstadt, Germany
20Children’s Hospital, Marien-Hospital Wesel gGmbH, Wesel, Germany
21Universitätsklinikum Erlangen, Children’s Hospital, Erlangen, Germany
222nd Pulmonary Medicine Department, National and Kapodistrian University of Athens, Medical School, “ATTIKON” University Hospital, Haidari, Greece
23SC Pneumologia - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Contributors MG managed the KLR database and designed the project. MG and YL analysed the data and wrote the manuscript. JL-Z, BK, JD and IK-S analysed the imaging data. SR-H analysed histology data. ES, KK, FG, MIEF, KM, IP, FG, FS, XY and CK contributed to data retrieval and registration organisation. J-C, MW, AMA-G, AT-V, JL, KK, NR, SM, TS, AA, NR, MP, FS, LN, KA, SB, CK-R, EP, EDOM, SAP, IC, HK and JS contributed cases, discussed the study results and contributed to the final manuscript. MG acts as the guarantor of the study.

Funding This work was supported by a grant from Ludwig-Maximilians-Universität München-China Scholarship Council (LMU-CSC) Scholarship Programme (grant to YL, 201608500066), the German Research Fund (DFG Gr 970/9-1) and childHDL (http://www.childlungfoundation.org/).

Competing interests None declared.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by the ethics committee of the Ludwig-Maximilians-University Munich (EK 111-13, 20-0329). Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as online supplemental information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMI does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Elias Seid http://orcid.org/0000-0001-6610-3756
Antonio Moreno-Galdó http://orcid.org/0000-0002-2496-9786
Alba Torrent-Vernetta http://orcid.org/0000-0002-3575-2427
Matthias Giere http://orcid.org/0000-0003-0113-912X

REFERENCES